Author‑focused paper audits

Evidence synthesis (concise, evidence-weighted)

• Computational/bioinformatics leadership: In the 2018 immunotherapy signatures paper the author list and contributions explicitly state "P.J. carried out the computational works" and "P.J. and J.F. developed the website", indicating an active computational lead role rather than a purely supervisory name-only credit — evidence from methods & acknowledgements shows funding & team support consistent with computational heavy-lifting (Cancer immunotherapy signatures (P.J. computational lead)
• Primary data & reproducible analysis claims: The 2024 honeybee virome preprint lists P.J. Hesketh-Best as performing bioinformatic analysis and delivering visualization and provides SRA accession codes plus a GitHub repo link — a reproducibility-positive sign though preprint status means peer review is pending (Honeybee virome preprint (P.J. bioinformatics author)
• Senior/PI-level work: In the human-mouse co-transplant preprint P.J. is named among senior authors who conceived and directed the work — indicates capacity to lead complex biological experiments integrating iPSC models with single-cell genomics (Human-mouse chimeric brain models (P.J. senior author)
• Mechanistic molecular biology contributions: DDX41 preprint (2024) shows mechanistic genetics and human iPSC corroboration; P.J. appears among data analysts/writers — again supports interdisciplinary skills at genetics/epigenetics interface (DDX41 G4 dissolution preprint (P.J. coauthor)

Interpretation & critical appraisal (short list)

1. Strengths: Repeated evidence of hands-on computational and analytic work (bioinformatics, visualization), integration with experimental teams, and involvement in technically complex projects (single-cell, iPSC organoids, multi-omic cancer signatures).
2. Weaknesses / blindspots: Most direct evidence in the supplied corpus is from preprints (bioRxiv) — not yet peer-reviewed; the supplied bibliometric author record (h-index = 0, citations = 0, 1 paper) contradicts the multi-paper coauthorships present here. This points to name ambiguity (common initials), inconsistent author disambiguation, or incomplete indexing in the supplied local author metadata. Before treating P.J. as a decisively high-impact author, verify identity via ORCID, institutional affiliation, and full author list in published journals.
3. Reproducibility assessment: Good signals where SRA accession numbers and GitHub links are provided (e.g., honeybee virome); for other preprints, request raw code and processed data if you will re-use analyses. Lack of peer review and possible absence of publicly-archived code in some papers reduces reproducibility confidence.
4. Conflict-of-interest & funding bias: several multi-author papers include declared competing interests for other coauthors; P.J. is sometimes the recipient of grants/fellowships (in older papers), but check each paper’s disclosure section carefully; no direct financial red flags for P.J. are evident in the supplied items.

What would change the conclusion (falsification criteria)

• If institutional/ORCID disambiguation shows the P.J. in the supplied preprints is a different person than the P.J. whose author metrics were given — the current attribution collapses.
• If peer review substantially revises or retracts major claims in the preprints where P.J. is a lead analyst — our confidence falls.

Actionable recommendations for the user (how to verify & use P.J.'s work)

1. Confirm the author's full name, ORCID, and institutional affiliation for unambiguous attribution before hiring/collaborating.
2. Request the exact GitHub / data accession links and a small reproducible analysis notebook for any key result you plan to rely on (the honeybee preprint already provides such links).
3. For policy or translational decisions, prefer peer-reviewed versions or replicate key analyses on the raw data (SRA) yourself or by an independent analyst.